Category: Events

  • The Way Forward

    The Way Forward

    Photos: Jon Derricott

    The Global Forum on Nicotine debates harm reduction in Liverpool and online.

    By George Gay

    If you’ve ever been involved in organizing a conference, one of the issues you will have run into will almost certainly have concerned how long people are given to speak. Among the organizing committee, there will have been those who thought 40 minutes was a reasonable slot while others would have tended toward 10 minutes. I have always leaned to the view that 10 minutes is too long to listen to one person speaking, so I was delighted to find that this year, for the first time, the Global Forum on Nicotine (GFN) included a series of five-minute videos.

    That’s the good news. The bad news, if you’re short of time, is that, at last count, there were about 75 of these videos, or GFN5s. That’s more than six hours in total. I have to confess to having watched only about half of them by the time I sat down to write this piece.

    There is little lost and much to gain in keeping presentations short and watching them as videos. Unlike in the case of live presentations, at your convenience and depending on your mood, you can watch a video or not depending on your interest in the subject under discussion. You can pause it and go back if you need to check something. And, if your interest is such that you want further information, most of the video makers provide details of how to go about finding it or making contact. Importantly, you can yell at the screen.

    The GFN5s formed part of the 8th Global Forum on Nicotine held June 17–18 at the Crowne Plaza Hotel in Liverpool, U.K., and virtually under the theme: “The future for nicotine.” The program comprised three keynote presentations: Science and Politics: An Often Fractious Relationship; Investments in Nicotine Innovation: Risks and Rewards for Public Health; and Why Has the WHO FCTC [Framework Convention on Tobacco Control] Failed to Reduce Adult Smoking and Its Health Impact? There were, in addition, four panel discussions: Science: Orthodoxy, Challenges and Dissent; Who Uses Nicotine and Why?; Obstacles to Tobacco Harm Reduction in LMICs [lower-income and middle-income countries]; and Safer Product Regulation: Supporting or Undermining the End of Smoking? The keynote and panel presentations were interspersed with the streaming of GFN5s and analyses by a commentary team, and toward the end of the event, there was a consumer voices panel.

    This was the first hybrid GFN, but conferencing with at least an element of virtual interaction has got to be the way ahead. There is little point, it seems to me, in constructing long-term strategies for reducing the harm caused by smoking tobacco if it means hundreds of people flying around the world, adding to a climate emergency that will “kill” us all anyway. I don’t know whether it was intentional, but there was a neat reference to such matters in one of the pre-panel-discussion videos, which were longer than the GFN5s. As one of the panelists delivered her presentation about the FCTC and tobacco harm reduction, hanging on the wall in the background was a print of London’s former Battersea power station belching out what looked like smoke. Having grown up in London with nonsmoking parents, my health would have been negatively affected more by the Battersea smoke and the general pollution of what was then a highly polluted city than by tobacco smoke.

    Fiona Patten MP

    Expanded Reach

    Virtual events clearly work. The effects of the Covid-19 pandemic meant that the GFN conference organizer, KAC Communications, was forced to move the 2020 conference online; but even though this had to be done at short notice, GFN20 reached a bigger audience than ever before. Two thousand people registered from more than 100 countries, a number that included many consumers from around the world who were able to join the event for the first time. Compare this with the 1,100 from 87 countries who registered for the 2021 event.

    There is, of course, considerable pressure building up among those who find virtual events unsatisfying and those with an interest in flying people around the world and putting them up in hotels. And KAC recognized this point in a pre-2021-event press release that, in part, said more than a year of online meetings had “taken their toll.” But, the organizer, which has a history of introducing innovative ideas to its conferences, reacted to this situation by aiming “to reenergize the digital format.” “A new GFN TV online platform will stream broadcast-quality footage of the conference free to viewers around the world, with a new commentary team offering their insights,” the press note said. This format worked well, in my estimation.

    Again, this must surely be the way ahead. It would be a tragic waste in my view if, after having been forced by the Covid-19 pandemic to look more closely at virtual or hybrid conferences, we abandoned them at the first opportunity. It will take time for people to adjust to the new virtuality, but they will do so, especially if the way is eased by using innovative techniques. How can THR advocates preach to tobacco smokers about the health benefits of moving to “virtual smoking” with electronic cigarettes if they are not willing for the sake of the climate—for the sake of everyone’s health—to move to virtual meetings?

    One of the great advantages of the GFN5s is that, while they offer the opportunity for the old lags to have another say, they also allow those watching to see and hear from people who they would not normally come across giving presentations at conferences—to learn things they probably wouldn’t have learned otherwise. What better reason to “attend” a conference? Having said that, I should point out that the GFN has always been an inclusive event. I attended the first GFN and learned a lot from a group of attendees whose main—and considerable—claim to expertise was that they were vapers and vaper advocates.

    Another advantage is that the videos, which aren’t all five minutes in length, cover a range of styles and levels of professionalism that help hold the attention—watch out for the duck in one of them—better than does the usual, largely unchanging backdrop of traditional conferences, which are often held in windowless hotel bunkers where natural light rarely penetrates—with, I would suggest, the inevitable consequences.

    Clive Bates, Robyn Gougelet and Michelle Minton

    The Heart of the Matter

    I would recommend that anybody interested in questions surrounding tobacco harm reduction take a look at these videos, but I shall draw attention to just two. I am not saying that these are the best of the bunch; I have, after all, listened to and watched fewer than half of them. But these two videos contained significant messages in my view. One, by John Oyston, a retired anesthesiologist, sought to answer the question of why many people working in the medical profession have not fully embraced the idea of tobacco harm reduction using electronic cigarettes, and made suggestions about how they might be brought on board in the future. It wasn’t that Oyston said anything new, but he brought to his presentation the insights and authority of a retired medical professional who had boiled down the salient points into a five-minute talk that, unlike some of the more data-filled presentations, got to the heart of the matter in a way that could be understood and appreciated by anybody. It deserves a wide audience.

    There was something a little disturbing about Oyston’s presentation, however. This was the eighth annual GFN, and we are still apparently in a position where we are casting about for ways to get medical professionals on board. Indeed, we are still trying to get many health professionals to understand that nicotine doesn’t cause cancer. And we still seem to be in the situation where we leave each annual conference with the same words ringing in our ears—we need to refute the bad science being put about so that the messaging changes and a large majority of people accept the idea that nicotine is not the problem and can be delivered in ways that are far safer than is the case with tobacco smoking. In fact, one of the messages that came across a number of times was that science was losing out to politics and ideology, with the result that nicotine was being shoehorned into the evil empire where tobacco dwells.

    This has to raise the question: do we need a plan B? Given that the object of the exercise is to encourage smokers to quit their habit, not necessarily the promotion of alternative nicotine-delivery systems, do we need to look at things again? At what point do we have to accept that, however wrong they might be, the people at the WHO and others opposed to THR have won?

    One of the disheartening aspects of the conference was to see on one of the panels an unusually subdued Konstantinos Farsalinos, a physician and senior researcher at the University of Patras and the University of West Attica’s National School of Public Health in Greece. Farsalinos’ work in demonstrating the validity or otherwise of THR science has been invaluable for the nonscientists among us. But in a recent piece on Qeios, he explains how a report by journalists in the BMJ had confused his work on an aspect of Covid-19 with unconnected THR research, and had wrongly accused him of the nondeclaration of interests. But worst of all for Farsalinos, I think, was the fact that he was not allowed a right of reply in the same journal.

    The next question that inevitably pops up, I guess, is outside the scope of the likes of GFN conferences. It concerns how it might be possible to encourage smokers to quit their habit without the use of nicotine alternatives. And here I mean “encourage.” What passes for “encouragement” among much of the tobacco control community is, to my way of thinking, “bullying.” It is largely about raising taxes to levels that render poorer the already financially impoverished. And in this respect, I was gladdened to hear one panelist point out that piling taxes and stigma on smokers is not ethical; indeed, it is reprehensible.

    And there was some encouragement here from my other choice of videos. This one, narrated by Kevin McGirr, concerned an observational study targeting tobacco-using individuals with substance use or mental health disorders—people who make up a disproportionate amount of smoking populations. What I particularly liked about this study was its humanity—the way it has been constructed to allow the researchers to work with smokers, not work on them. Participants, who have to have shown some interest in altering their smoking habits, might not have abstinence as their final goal, which they set themselves. The researchers do not even use the term cessation.

    Conference founder Gerry Stimson

    A Breath of Fresh Air

    Meanwhile, the conference allowed participants also to access in advance of the panel discussions videos made by some of the panelists. Again, these were worth watching, but I will draw attention to just two, which addressed, in part, an issue that many people within THR find almost incomprehensible—at least in a rational world. Why, when apparently most people are desperate to reduce toward zero the health problems caused by tobacco smoking and after more than 10 years of the cause of THR being supported by less risky products that some smokers find can substitute for cigarettes, has the idea of THR not gained more traction? Brad Rodu clearly demonstrated in his presentation how part of the reason in the U.S. is down to the way that most scientific research funding is made. In the other presentation, Michelle Minton explained how government policies in the U.S. are driven by the fears and wishes of the majority population, made up of the suburban, white middle classes. This is why tobacco smoking, a habit mainly of the financially less well-off, has been largely tolerated, while vaping, the subject of scare stories about an epidemic among the children of the middle class, has launched a moral panic.

    Interestingly, given that THR has failed to gain the traction that logic suggests it should have, we were told during the conference that the FCTC was fit for purpose. I should point out that this statement was made in respect of the treaty’s text and the way it provided for parties to the treaty to embrace THR. It was not a comment about whether or how effectively THR principles had been applied. But given what has happened, it does raise a question about what is this “purpose” that it is fit for? After all, the nations of the world didn’t have to rely on the establishment of the treaty to embrace THR. It has always been my view that creating an international treaty around a legal consumer product was simply an extravagant and bizarre exercise in bureaucracy whose purpose was the creation of an endless series of environment-destroying conferences. Indeed, this sense of endlessness was suggested in a comment by one of the people associated with the FCTC when he prefaced a comment with: “If we are to finally end the use of combustible cigarettes …” There is a sense that we are content to drift from conference to conference, chewing over the same ideas and getting almost nowhere: in fact, in many places stagnating or even going backward.

    So it was good that the Australian MP, Fiona Patten, a Member for the Northern Metropolitan Region in the Victorian Parliament’s Legislative Council and leader of the Reason Party, who gave the first—remote—keynote presentation, brought a breath of fresh air into the proceedings. Patten was clearly frustrated at the irrationality of Australia’s politicians who for a long time ignored the science about the dangers of tobacco smoking and today are arguing that there is not enough science to sanction alternative nicotine products. She was funny and feisty and clearly determined to get her way in respect of THR. And perhaps she will. As she, and others at the GFN pointed out, if the Covid-19 pandemic has delivered one positive, it is that politicians have been forced to listen to scientists.

    Being a man and not a scientist, I wasn’t able to follow the complex reasoning through which Patten compared the clitoris with vaping devices, but the images conjured up did remind me briefly of a till-then long-forgotten Billy Connelly story about changing batteries in small electrical devices. And I would like to conclude by saying that it is surely time to give much more attention at THR conferences to considering the relative environmental impacts of tobacco and nicotine products. If we did end up converting 1.1 billion smokers worldwide to vaping, that would be an awful lot of batteries.

    The organizer will be making GFN presentations available as individual sessions shortly, but for the time being, Day 1 presentations are available here.

    The GFN is due to return to its live format and its “home” in Warsaw, Poland, next year on June 16–18.

     

  • Nicotine Forum Focuses on Harm Reduction

    Nicotine Forum Focuses on Harm Reduction

    Photo: alpegor

    Policymakers in public health and tobacco control need to listen to both the science on tobacco harm reduction and the experiences of consumers who are benefiting from it every day. Ideology must be set aside to prioritize progress toward the common goal of ending smoking. Those were some of the messages conveyed during the Global Forum on Nicotine (GFN), which took place June 16–18 in Liverpool, U.K.

    Gerry Stimson, Emeritus Professor at Imperial College London and a founder of the GFN, said that much of what she has seen and heard during the event was encouraging.

    “It feels as though we’re on the right trajectory,” he said. “Consumers all over the world are becoming aware of the opportunities offered by safer nicotine products, and innovations in the market will, I believe, lead to the eventual obsolescence of combustible cigarettes,” she said. “The question is how to speed up the process and scale up so that tobacco harm reduction reaches all smokers, everywhere, as quickly as possible.”

    Multiple panel discussions took in subjects ranging from safer nicotine product regulation, tobacco harm reduction in low-income to middle-income countries and orthodoxy and dissent in science. Speakers’ prerecorded presentations for the panel sessions will remain available online at the conference website.

    Three keynotes were delivered to honor Michael Russell, a psychiatrist, research scientist and pioneer in the study of tobacco dependence and the development of treatments to help smokers quit. Russell’s observation in the British Medical Journal in 1976 that “people smoke for nicotine, but they die from the tar” remains highly influential within the field.

    The speeches honoring Russel focused on harm reduction and were given by Fiona Patten, leader of Australia’s Reason Party; Jon Fell, founder of investment company Ash Park; and Derek Yach, president of the Foundation for a Smoke-Free World.

    “In Australia, governments have consistently stated that drug use must be treated as a health issue not a criminal one. But when it comes to nicotine, they are actively making criminals out of users,” Patton said. “For decades, they ignored the science about the dangers of smoking, but today, they argue that there is not enough science to sanction alternative nicotine products.”

    GFN does not receive any sponsorship from manufacturers, distributors or retailers of nicotine products, including pharmaceutical, electronic cigarette and tobacco companies. Participants include consumers, policymakers, academics, scientists and public health experts alongside representatives from manufacturers and distributors of safer nicotine products.

    The event organizers believe that dialogue and strategic engagement of all stakeholders involved in tobacco and nicotine use, control and production are the only way to effect true, sustainable change—both to industry practices and the public health outcomes related to smoking.

  • Experts Call For Global Access to Safer Nicotine

    Experts Call For Global Access to Safer Nicotine

    Photo: Aleksej

    International public health specialists, scientists, doctors, tobacco control experts and consumers are convening for the Global Forum on Nicotine 2021 June 17 and 18 in Liverpool, U.K., and streaming free online, to highlight the vital role of safer nicotine products in the fight to reduce global smoking-related death and disease.

    Experts at the forum will discuss tobacco harm reduction, a concept that calls for encouraging adult smokers who cannot quit nicotine to switch from dangerous combustible or oral products to safer nicotine products, including e-cigarettes, pasteurized snus, nontobacco nicotine pouches and heated-tobacco devices.

    “Up to 98 million consumers worldwide have already made the switch to safer nicotine products,” said GFN director Gerry Stimson, emeritus professor at Imperial College London, in a statement.

    Public health will not be served nor lives saved by a war on nicotine, as doomed to failure as the war on drugs. The WHO must refocus its efforts on supporting 1.1 billion adult smokers to quit by all available means.

    “In England, health authorities support vaping to quit smoking, and vapes are now the most popular quit aid. Tobacco-related mortality in Sweden, where snus has almost replaced smoking, is the lowest in Europe. And in Japan, cigarette sales have dropped by a third since heated-tobacco products came to market. Manufacturers must now ensure safer alternatives are affordable to people in LMIC [low- to middle-income countries], not just consumers in high income nations,” he said.

    “Worryingly, international tobacco control leaders are doggedly pursuing an irresponsible prohibitionist approach to tobacco and nicotine, while the WHO actively perpetuates misinformation on new nicotine products. Public health will not be served nor lives saved by a war on nicotine, as doomed to failure as the war on drugs. The WHO must refocus its efforts on supporting 1.1 billion adult smokers to quit by all available means.”

  • Rooting for Science

    Rooting for Science

    Photo: BAT

    Participants in the In Focus: THR conference examined the state of tobacco harm reduction in a critical year for the subject.

    By Stefanie Rossel

    The year 2021 will be critical for tobacco harm reduction (THR). In November, the ninth session of the Conference of the Parties (COP9) to the World Health Organization’s Framework Convention on Tobacco Control will take place. The European Union recently introduced its Beating Cancer Plan, which aims to reduce tobacco use in the EU to less than 5 percent by 2040 and commits to significantly strengthen tobacco-control measures in the union. It coincides with a review of the EU Tobacco Products Directive, scheduled to begin this month, that will consider amendments to take account of next-generation products (NGPs), many of which did not exist or were in their infancy when the original directive took effect years ago.

    The first “In Focus” virtual conference, organized by the GTNF Trust and held on April 27, shed some light on the challenges and opportunities for THR. The open mic session, moderated by Counterfactual Director Clive Bates, probably summed up best what is going well and what is going badly in THR. On the positive side, panelists noted that, thanks to continuous innovation in the corporate sector, consumers now have a vast choice of alternative products that are fundamentally better than combustible cigarettes. In the United States, the leading market for vape products, the Food and Drug Administration has started to process premarket tobacco product application (PMTA) submissions. Significantly, it approved Philip Morris International’s IQOS tobacco-heating product as a modified-risk product in 2020.

    The negative list, however, is much longer: Several countries tax e-cigarettes like combustible cigarettes. The tobacco industry appears to have no chance to restore its bad reputation—whatever it is doing, it must be counteracted, in the view of its detractors. The points most frequently mentioned by panelists were misperception of the risk of nicotine and the misperception that reduced-risk products (RRPs) are in fact more harmful than combustible cigarettes. Both have led to bad public health policies, such as flavor bans, rules that make distribution of NGPs more difficult or outright prohibition of vapor products. “Correcting misperception of nicotine and RRPs is essential to spreading the concept of THR,” said Maria Gogova, vice president and chief scientific officer, Altria Client Services. “Data show that consumers who are informed about relative risks are more likely to switch to RRPs.”

    Cliva Bates
    Maria Gogova
    David Abrams

    No magic bullets

    Almost two decades after Hon Lik invented the modern e-cigarette, there is a plethora of THR studies, according to Professor Riccardo Pelosa, professor of internal medicine at the University of Catania, Italy, and founder of the Center of Excellence for the Acceleration of Harm Reduction. “However, THR research is in need of critical reform,” he argued. “Many THR studies have common methodological problems or a flawed study design. Rigorous THR research is not an obstacle but an asset to reduce divisions among tobacco control researchers. We need extensive research that shows the effect of switching in fewer illnesses and deaths.”

    Making science prevail over ideology remains a daunting task, said Professor David Abrams from the Department of Social and Behavioral Sciences at New York University. He lamented the proliferation of “zombie ideas,” such as the claim that e-cigarettes don’t help quitting, that keep resurfacing without supporting evidence. “There is no magic bullet against them,” he said. “We can’t expect those with the strongest convictions to change their minds quickly or easily—or ever. But those without such intense effects will come to recognize that harm reduction opponents lack an evidence base compared to those supporting the risk continuum.” Abrams recommended a focus on acts of scientific virtue, such as openness and humility, and said there was a need to engage in good faith with those who disagree.

    Despite the abundance of THR research, scientists are still seeking to fill gaps. Many of those gaps relate to real-world use of electronic nicotine-delivery systems (ENDS). It remains unclear, for example, to what extent vape products differ in effectiveness in assisting smoking cessation. To help answer that question, Neil McKeganey, director of the Center for Substance Use Research at the University of Glasgow, is carrying out The Big Vape Survey.

    Mark Kehaya
    Neil McKeganey
    Riccardo Polosa

    Over a period of 12 months, his team will collect data on 30,000 current adult smokers, looking at aspects such as ENDS purchase at the baseline and at follow-up, combustible cigarette use, patterns of e-cigarette use, intentions to quit smoking and nicotine strength and flavor choices. The output, McKeganey related, will provide a deeper understanding of the interaction between individual customers and individual devices. A similar survey in the U.S. will investigate the impact of reduced product variety. Since September 2020, ENDS manufacturers may sell their products only if they have submitted a PMTA.

    AMV Holdings, one of the largest independent specialty vape retailers in the U.S., has conducted several consumer surveys since 2015. Chairman Mark Kehaya shared the results of the most recent one from 2019. Seeking to measure how effective AMV is in weaning smokers off cigarettes, the poll looked at the behavior of almost 10,000 present and former customers for more than 12 months. Ninety percent of respondents used traditional tobacco products before they started using ENDS. Thirty percent of them had been smoking more than a pack of cigarettes per day; 50 percent had been smoking for more than 10 years. Ninety percent of respondents chose e-liquids with nontobacco flavors—for AMV, Kehaya pointed out, fruit is the single biggest category. After 12 months, the repeat range was between 72 percent and 73 percent. Sixty percent reported success in using ENDS to quit cigarettes, whereas 42 percent said they would eventually quit using ENDS as well. A reduction of nicotine strength in e-liquids was also observed. “ENDS are a significant means of getting people out of combustible cigarettes in an effective way, and flavors play an important role,” Kehaya concluded.

    A poll of 2,000 U.S. consumers conducted by Reynolds American (RAI) earlier this year demonstrated how widespread misperceptions of RRPs and nicotine are. While 70 percent of respondents believed that THR was a positive thing for public health in the U.S., only 16 percent thought that vaping was better for health than smoking combustible cigarettes, according to James Murphy, executive vice president of R&D and scientific and regulatory affairs at RAI. Eighty-two percent believed that nicotine was linked to cigarette-related mortality. “This misperception restricts the movement of smokers to less hazardous products,” said Murphy, who also hinted at the challenge of assessing the risk profiles of NGPs for which no epidemiological data are available yet. Modern oral products, such as nicotine pouches, have shown even lower toxicity and chemistry levels than the well-researched traditional oral products, such as moist snuff and Swedish-style snus.

    James Murphy
    Kgosi Letlape
    James Glassman

    Wanted: A new approach

    To make the WHO’s fight against global tobacco consumption more efficient, the COP9 would be well advised to change its stance toward THR, according to the participants in the In Focus forum.

    Clive Bates invited his panelists to a mind game, asking them about the elements their policy would include if they were the WHO. Karl Fagerstrom, president of Fagerstrom Consulting, suggested that the system of alcohol regulation in which the alcohol concentration is decisive for the risk attributed to it could also be applied to tobacco. “In the case of tobacco, it would not be the nicotine concentration, but the hazard of the individual product,” he said. “This, however, requires that people are informed about the nature of nicotine and the continuum of risk.”

    Regarding knowledge gaps, Kgosi Letlape, former president of the Health Professions Council of South Africa, noted that the way in which people have been socialized in countries such as his presents a formidable challenge. “After 400 years of colonization, there is no cultivation of independent thought,” he said. “We have become a zombie nation, relying on the WHO to tell us what to think. People need to be given reliable information to make differentiated choices.”

    By 2030, more than 80 percent of tobacco-related deaths will occur in low-income and middle-income countries (LMICs), according to Ambassador James K. Glassman, former U.S. undersecretary of state for public diplomacy and public affairs and chairman of Glassman Advisory.

    Since September, Glassman has been chairman of the Commission to Reignite the Fight against Smoking, which is being sponsored by the Foundation for a Smoke-Free World. The committee is currently working on a report that focuses on how tobacco harm reduction can be leveraged to LMICs.

    It is scheduled to be finished by September—well in time for the COP9.

  • Forum on Nicotine to Convene in Liverpool

    Forum on Nicotine to Convene in Liverpool

    Photo: alpegor

    KAC Communications will be hosting the Eighth Global Forum on Nicotine (GFN) from June 17–18 at the Crowne Plaza Hotel in Liverpool, U.K. With its theme “The future for nicotine,” the GFN tackles the challenges and controversies, as well as the significant potential, of safer nicotine products. Participants can choose whether to attend in person or online. In-person registration costs £60 ($84.23) for two days, and online registration is free. 

    A new GFN∙TV online platform will stream broadcast footage of the conference free to viewers around the world, with a new commentary team offering their insights. 

    The GFN will feature more than 30 speakers from diverse backgrounds, including consumers, advocates, policy experts, public health specialists and medical professionals. All sessions will be live, with speaker presentations available on the GFN website before the event.

    “It’s a fallacy that tobacco control and harm reduction are irreconcilable as many believe—they’re complementary,” said Paddy Costall of KAC Communications. “While tobacco control has reduced smoking rates in many places, it’s got its limits. In the U.K. and elsewhere, it’s been shown that access to appropriately regulated safer nicotine products helps people stop smoking.

    “At GFN, we offer an inclusive platform to discuss all aspects of nicotine use, and we believe it’s important that no one is excluded from the debate. With one billion smoking-related deaths predicted by the end of this century, it’s time for ideology to make way for pragmatism.”

    For more information, visit https://gfn.events

  • Smoker Group Forest to Host Webinar on Vaping

    Smoker Group Forest to Host Webinar on Vaping

    Simon Clark

    To mark the last week of VApril, the U.K.’s annual vaping awareness month now in its fourth year, the smokers’ lobby group Forest is hosting a webinar on April 28 to discuss “Should smokers switch to vaping?”

    “E-cigarettes have been a mainstream consumer product for the best part of a decade, and vaping is credited with encouraging millions of smokers to switch to what evidence suggests is a significantly reduced-risk product,” says Forest director Simon Clark.

    “Despite that, millions more seem resistant to switching, and the latest figures suggest that the number of vapers in the U.K. may have fallen from a peak of 3.6 million to 3 million. The question is, why?”

    Speakers at the virtual meeting include John Dunne, CEO of the U.K. Vaping Industry Association; Joe Dunne, spokesperson for Respect Vapers in Ireland; and Daniel Pryor, head of programs at the Adam Smith Institute think tank.

    “Confirmed smokers are often excluded from public debates about vaping and smoking cessation,” says Clark. “It’s misguided because their views are essential to understanding why more smokers don’t want to quit or switch.

    Confirmed smokers are often excluded from public debates about vaping and smoking cessation.

    “We believe adults should have the freedom to make informed choices, so this is an opportunity for confirmed smokers to learn more about reduced-risk products, and for vaping advocates to understand why many smokers still prefer combustible tobacco and to respect that choice.”

    Forest’s webinar will take place on April 28 from 18:00–19:00 U.K. time.

    For further information and to register, click here.

  • Half-Day Tobacco Harm Reduction Conference

    Half-Day Tobacco Harm Reduction Conference

    The GTNF Trust will present a special half-day virtual conference on April 27, titled In Focus: Tobacco Harm Reduction, to help participants evaluate the science on tobacco harm reduction products and address the challenges and opportunities that lie ahead.

    The conference comes at a critical time. This year, the World Health Organization will host its Conference of the Parties for the Framework Convention on Tobacco Control. Meanwhile, the EU is pressing ahead with its newly launched Beating Cancer Plan and drafting the next Tobacco Products Directive.

    Panelist in the In Focus: Tobacco Harm Reduction conference include:

    • David Abrams, professor in the department of social and behavioral sciences at New York University;
    • Mark Kehaya, chairman of AMV Holdings;
    • Maria Gogova, vice president and chief scientific officer at Altria Client Services;
    • Karl Fagerstrom, president of Fagerstrom Consulting;
    • Delon Human, president of Health Diplomats;
    • Jasjit S. Ahluwalia, professor of behavioral and social sciences and professor of medicine at the Center for Alcohol and Addiction Studies, Brown University School of Public Health and Alpert School of Medicine;
    • Riccardo Polosa, full professor of internal medicine at the University of Catania and founder of the Center of Excellence for the Acceleration of Harm Reduction;
    • James Murphy, executive vice president of R&D and scientific and regulatory affairs at Reynolds American; and
    • Roxana Weil, senior director of product integrity and toxicology at Juul Labs.

    For more information and registration, please visit infocusthr.org.

  • Intertabac Exhibition Postponed Again

    Intertabac Exhibition Postponed Again

    Photo: Westfalenhallen Unternehmensgruppe

    The Intertabac and Intersupply 2021 trade shows will not take place due to the ongoing coronavirus pandemic. Billed as the world’s largest tobacco trade show, the event was scheduled to take place Sept. 16–18, 2021, in Dortmund, Germany. Westfalenhallen Unternehmensgruppe, the owner of the Intertabac show, announced today that the event is cancelled after talking with exhibitors and sponsors.

    Working closely with the industry associations and partner associations, the conceptual sponsors, the advisory board and the exhibitors of the twin fairs, it has become clear that the vast majority is against holding the events this September.

    “Working closely with the industry associations and partner associations, the conceptual sponsors, the advisory board and the exhibitors of the twin fairs, it has become clear that the vast majority is against holding the events this September as previously announced,” said Sabine Loos, managing director for Westfalenhallen Unternehmensgruppe, in a statement.

    Intertabac showcases nearly every product that is associated with consuming nicotine, from vaping products and combustible cigarettes to machine-made and premium cigars, pipes, shisha, smokeless and other tobacco-related products. In 2019, 13,800 people attended the event, which had more than 500 exhibitors from 47 countries, according to Intertabac.

    Last year’s event was also cancelled. Intertabac 2022 is scheduled for Sept. 15–17, 2022, according to Westfalenhallen Unternehmensgruppe .

  • Women in Tobacco to Celebrate Women’s Day

    Women in Tobacco to Celebrate Women’s Day

    Women in Tobacco (WIT) will celebrate International Women’s Day on March 8 with a virtual meeting starting at 16:30 U.K. time.

    During the meeting, WIT will highlight the work of two female authors—Karen Blakeley and Katherine Graham.

    Blakeley, who previously published a book on change management, will offer a sneak preview of her latest work, Leading with Love, which is scheduled for release in July. Graham, previously with Japan Tobacco International in Geneva and London, will share excerpts from her debut novel, Salt Sisters, which will be published on March 11. 

    Participants in the WIT meeting will have an opportunity to win a signed copy of each book.

    Click here for more information about the meeting and the authors. To register, please contact Kathryn Kyle.

  • ITGA Announces Annual Meeting

    ITGA Announces Annual Meeting

    The International Tobacco Growers’ Association will hold its annual meeting Nov. 18-20, 2020.

    Speakers include President Abiel M. Kalima Banda, Chief Executive Antonio Abrunhosa, tobacco industry expert Ivan Genov and Shane MacGuill, head of tobacco research at Euromonitor International.

    The gathering will take place virtually and registration will be available shortly here.